Physician profile
Isaac Tabari
NPI 1487649059
$2,752.92
in general payments reported to CMS, 2019-2025
13 companies · $175 in 2025
The $175 reported for 2025 was less than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $529 · 2021: $474 · 2022: $376 · 2023: $595 · 2024: $281 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $1,209.99 | 2020-2025 | Nuzyra |
| Smith+Nephew, INC. | $1,044.72 | 2019-2025 | Collagenase Santyl, Regranex |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $93.15 | 2019 | |
| Boston Scientific Corporation | $88.34 | 2020 | |
| Melinta Therapeutics, LLC | $65.86 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $48.59 | 2023 | Seglentis |
| Nevro Corp. | $48.08 | 2023-2024 | Senza |
| Amgen INC. | $46.86 | 2025 | Krystexxa |
| Sebela Pharmaceuticals INC. | $42.45 | 2022-2023 | Pramosone, Naftin |
| Nabriva Therapeutics, Plc | $18.01 | 2022 | |
| Novum Pharma, LLC | $17.01 | 2019 | |
| Globus Medical, INC. | $15.98 | 2025 | Senza |
| Dynasplint Systems INC. | $13.88 | 2024 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Tabari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.